Nippon Shinyaku Co Ltd 2017 AR2
The report highlights Nippon Shinyaku's business performance and ESG initiatives for fiscal 2016. The company achieved record-high financial results, with net sales increasing by 17.3% to ¥98,781 million, driven by strong sales of new pharmaceuticals like Zalutia, Vidaza, and the newly launched Uptravi. In R&D, the company advanced its pipeline, notably receiving fast track and orphan drug designations in the U.S. for its Duchenne muscular dystrophy treatment NS-065/NCNP-01. On the environmental front, the company successfully completed its 4th Environmental Targets Plan, achieving a 13.7% reduction in total energy consumption compared to fiscal 1990 and reducing landfilled waste by 81.5% compared to fiscal 2005.
Company: Nippon Shinyaku Co Ltd
Sector: Health Care
Country: Japan
Year: 2017
Type: AR2
Pages: 29
Nippon Shinyaku Co Ltd
Annual Report
The report highlights Nippon Shinyaku's business performance and ESG initiatives for fiscal 2016. The company achieved record-high financial results, with net sales increasing by 17.3% to ¥98,781 million, driven by strong sales of new pharmaceuticals like Zalutia, Vidaza, and the newly launched Uptravi. In R&D, the company advanced its pipeline, notably receiving fast track and orphan drug designations in the U.S. for its Duchenne muscular dystrophy treatment NS-065/NCNP-01. On the environmental front, the company successfully completed its 4th Environmental Targets Plan, achieving a 13.7% reduction in total energy consumption compared to fiscal 1990 and reducing landfilled waste by 81.5% compared to fiscal 2005.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Apr 1, 2016 - Mar 31, 2017
Fiscal Year
2016
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Employees